Literature DB >> 18332465

Dose selection in phase I studies: why we should always go for the top.

Stefan Sleijfer, Erik Wiemer.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18332465     DOI： 10.1200/JCO.2007.15.5192

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

Review 1.  Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Authors:  Christophe Le Tourneau; Véronique Diéras; Patricia Tresca; Wulfran Cacheux; Xavier Paoletti
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

Review 2.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

3.  Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.

Authors:  Nicolas Penel; Alain Duhamel; Antoine Adenis; Patrick Devos; Nicolas Isambert; Stéphanie Clisant; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

4.  Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

Authors:  Randy F Sweis; Michael W Drazer; Mark J Ratain
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

Review 5.  Maximum tolerated dose: clinical endpoint for a bygone era?

Authors:  Chris H Takimoto
Journal:  Target Oncol       Date:  2009-04-18       Impact factor: 4.493

6.  A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.

Authors:  Jun Yin; Rui Qin; Monia Ezzalfani; Daniel J Sargent; Sumithra J Mandrekar
Journal:  Stat Med       Date:  2016-09-15       Impact factor: 2.373

7.  Optimizing bevacizumab dosing in glioblastoma: less is more.

Authors:  Abdulrazag Ajlan; Piia Thomas; Abdulrahman Albakr; Seema Nagpal; Lawrence Recht
Journal:  J Neurooncol       Date:  2017-06-30       Impact factor: 4.130

Review 8.  Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Authors:  Daniel Crona; Federico Innocenti
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

Review 9.  Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.

Authors:  Ruirong Yuan; Andrea Kay; William J Berg; David Lebwohl
Journal:  J Hematol Oncol       Date:  2009-10-27       Impact factor: 17.388

10.  Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Authors:  S Postel-Vinay; H-T Arkenau; D Olmos; J Ang; J Barriuso; S Ashley; U Banerji; J De-Bono; I Judson; S Kaye
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.